The ELF3 Transcription Factor is Associated with an Epithelial Phenotype and Represses Epithelial-mesenchymal Transition

Overview

Journal J Biol Eng

Publisher Biomed Central

Specialty Biomedical Engineering

Date 2023 Mar 2

PMID 36864480

Authors

Ayalur Raghu Subbalakshmi

Sarthak Sahoo

Prakruthi Manjunatha

Shaurya Goyal

Vignesh A Kasiviswanathan

Yeshwanth Mahesh

Soundharya Ramu

Isabelle McMullen

Jason A Somarelli

Mohit Kumar Jolly

Affiliations

Soon will be listed here.

Abstract

Background: Epithelial-mesenchymal plasticity (EMP) involves bidirectional transitions between epithelial, mesenchymal and multiple intermediary hybrid epithelial/mesenchymal phenotypes. While the process of epithelial-mesenchymal transition (EMT) and its associated transcription factors are well-characterised, the transcription factors that promote mesenchymal-epithelial transition (MET) and stabilise hybrid E/M phenotypes are less well understood.

Results: Here, we analyse multiple publicly-available transcriptomic datasets at bulk and single-cell level and pinpoint ELF3 as a factor that is strongly associated with an epithelial phenotype and is inhibited during EMT. Using mechanism-based mathematical modelling, we also show that ELF3 inhibits the progression of EMT. This behaviour was also observed in the presence of an EMT inducing factor WT1. Our model predicts that the MET induction capacity of ELF3 is stronger than that of KLF4, but weaker than that of GRHL2. Finally, we show that ELF3 levels correlates with worse patient survival in a subset of solid tumour types.

Conclusion: ELF3 is shown to be inhibited during EMT progression and is also found to inhibit the progression of complete EMT suggesting that ELF3 may be able to counteract EMT induction, including in the presence of EMT-inducing factors, such as WT1. The analysis of patient survival data indicates that the prognostic capacity of ELF3 is specific to cell-of-origin or lineage.

Citing Articles

An integrative phenotype-structured partial differential equation model for the population dynamics of epithelial-mesenchymal transition.

Guilberteau J, Jain P, Jolly M, Pouchol C, Pouradier Duteil N NPJ Syst Biol Appl. 2025; 11(1):24.

PMID: 40050291 PMC: 11885588. DOI: 10.1038/s41540-025-00502-4.

Multi-omics integration analysis of the amino-acid metabolism-related genes identifies putatively causal variants of ACCS associated with hepatitis B virus-related hepatocellular carcinoma survival.

Wei X, Yang X, Duan S, Lin Q, Qiu M, Wen Q BMC Cancer. 2025; 25(1):284.

PMID: 39966747 PMC: 11834470. DOI: 10.1186/s12885-025-13604-3.

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.

Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S Sci Rep. 2025; 15(1):4294.

PMID: 39905117 PMC: 11794704. DOI: 10.1038/s41598-024-82218-9.

Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4-/- Mice.

Di Giorgio C, Urbani G, Marchiano S, Biagioli M, Bordoni M, Bellini R Liver Int. 2025; 45(2):e16235.

PMID: 39804015 PMC: 11727439. DOI: 10.1111/liv.16235.

Overexpression of ELF3 in the PTEN-deficient lung epithelium promotes lung cancer development by inhibiting ferroptosis.

Yuan Z, Han X, Xiao M, Zhu T, Xu Y, Tang Q Cell Death Dis. 2024; 15(12):897.

PMID: 39695109 PMC: 11655876. DOI: 10.1038/s41419-024-07274-5.

References

Sengez B, Aygun I, Shehwana H, Toyran N, Tercan Avci S, Konu O . The Transcription Factor Is Essential for a Successful Mesenchymal to Epithelial Transition. Cells. 2019; 8(8). PMC: 6721682. DOI: 10.3390/cells8080858. View

Chakrabarti R, Hwang J, Blanco M, Wei Y, Lukacisin M, Romano R . Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol. 2012; 14(11):1212-22. PMC: 3500637. DOI: 10.1038/ncb2607. View

Davis S, Meltzer P . GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007; 23(14):1846-7. DOI: 10.1093/bioinformatics/btm254. View

Piggin C, Roden D, Law A, Molloy M, Krisp C, Swarbrick A . ELF5 modulates the estrogen receptor cistrome in breast cancer. PLoS Genet. 2020; 16(1):e1008531. PMC: 6959601. DOI: 10.1371/journal.pgen.1008531. View

Watanabe K, Liu Y, Noguchi S, Murray M, Chang J, Kishima M . OVOL2 induces mesenchymal-to-epithelial transition in fibroblasts and enhances cell-state reprogramming towards epithelial lineages. Sci Rep. 2019; 9(1):6490. PMC: 6482152. DOI: 10.1038/s41598-019-43021-z. View

Li D, Cheng P, Wang J, Qiu X, Zhang X, Xu L . IRF6 Is Directly Regulated by ZEB1 and ELF3, and Predicts a Favorable Prognosis in Gastric Cancer. Front Oncol. 2019; 9:220. PMC: 6458252. DOI: 10.3389/fonc.2019.00220. View

Kumegawa K, Takahashi Y, Saeki S, Yang L, Nakadai T, Osako T . GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. NPJ Breast Cancer. 2022; 8(1):70. PMC: 9177858. DOI: 10.1038/s41523-022-00438-6. View

Wu C, Zhu W, Qian J, He S, Wu C, Chen Y . WT1 promotes invasion of NSCLC via suppression of CDH1. J Thorac Oncol. 2013; 8(9):1163-9. DOI: 10.1097/JTO.0b013e31829f6a5f. View

Tripathi S, Levine H, Jolly M . The Physics of Cellular Decision Making During Epithelial-Mesenchymal Transition. Annu Rev Biophys. 2020; 49:1-18. DOI: 10.1146/annurev-biophys-121219-081557. View

10.

Chung V, Tan T, Ye J, Huang R, Lai H, Kappei D . The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells. Commun Biol. 2019; 2:272. PMC: 6656769. DOI: 10.1038/s42003-019-0506-3. View

11.

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

12.

Lou Z, Lee B, Ha T, Xu Y, Kim H, Kim C . ESE‑1 suppresses the growth, invasion and migration of human NSCLC cells and tumor formation in vivo. Oncol Rep. 2018; 40(3):1734-1742. DOI: 10.3892/or.2018.6560. View

13.

Sterneck E, Poria D, Balamurugan K . Slug and E-Cadherin: Stealth Accomplices?. Front Mol Biosci. 2020; 7:138. PMC: 7371942. DOI: 10.3389/fmolb.2020.00138. View

14.

Yang Z, Wu D, Chen Y, Min Z, Quan Y . GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition. Cancer Biol Ther. 2019; 20(9):1195-1205. PMC: 6741563. DOI: 10.1080/15384047.2019.1599664. View

15.

Kar A, Gutierrez-Hartmann A . ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2 breast cancer patients and is critical for tumorigenesis in HER2 breast cancer cells. Oncotarget. 2017; 8(41):69622-69640. PMC: 5642504. DOI: 10.18632/oncotarget.18710. View

16.

Wang Z, Yin P, Sun Y, Na L, Gao J, Wang W . LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits. Gynecol Oncol. 2020; 159(3):839-849. DOI: 10.1016/j.ygyno.2020.09.020. View

17.

Zhang J, Tian X, Zhang H, Teng Y, Li R, Bai F . TGF-β-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci Signal. 2014; 7(345):ra91. DOI: 10.1126/scisignal.2005304. View

18.

Farris J, Pifer P, Zheng L, Gottlieb E, Denvir J, Frisch S . Grainyhead-like 2 Reverses the Metabolic Changes Induced by the Oncogenic Epithelial-Mesenchymal Transition: Effects on Anoikis. Mol Cancer Res. 2016; 14(6):528-38. PMC: 4912396. DOI: 10.1158/1541-7786.MCR-16-0050. View

19.

Yeung T, Leung C, Wong K, Gutierrez-Hartmann A, Kwong J, Gershenson D . ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget. 2017; 8(10):16951-16963. PMC: 5370013. DOI: 10.18632/oncotarget.15208. View

20.

Somarelli J, Shetler S, Jolly M, Wang X, DeWitt S, Hish A . Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2. Mol Cell Biol. 2016; 36(19):2503-13. PMC: 5021378. DOI: 10.1128/MCB.00373-16. View